J Korean Med Sci.  2020 Jul;35(29):e269. 10.3346/jkms.2020.35.e269.

IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea

• Song SK
• Lee DH
• Nam JH
• Kim KT
• Do JS
• Kang DW
• Kim SG
• Cho MR

• KMID: 2504703
• DOI: http://doi.org/10.3346/jkms.2020.35.e269

Abstract

Background
Seroprevalence studies of coronavirus disease 2019 (COVID-19) from many countries have shown that the number of undiagnosed missing cases is much larger than that of confirmed cases, irrespective of seroprevalence levels. Considering the strategy of Korea entailing massive testing and contact tracing from the beginning of epidemic, the number of undiagnosed missing cases in Korea may be negligible. This study was conducted to estimate the seroprevalence of COVID-19 among individuals who were never diagnosed with COVID-19 in Daegu, the epicenter of COVID-19 epidemic in Korea.
Methods
Serologic testing for immunoglobulin G antibody based on immunochromatographic assay was conducted in 103 patients and 95 guardians aged 18 to 82 years without any history of COVID-19 diagnosis, who visited outpatient clinics of a single university-affiliated hospital from May 25 to June 5, 2020.
Results
The estimated seroprevalence was 7.6% (95% confidence interval, 4.3%–12.2%) with 15 positive cases. Among them, only one had a polymerase chain reaction (PCR)-confirmed case among their close contacts and 13 did not experience COVID-19-related symptoms. Seroprevalence was similar between patients and guardians. Based on this figure, the number of undiagnosed missing cases in Daegu was estimated to be a dozen times more than the number of confirmed cases based on PCR testing.
Conclusion
Despite the limitation of a small and unrepresentative sample, this is the first study on seroprevalence of COVID-19 in Korea. Our study suggested that the number of undiagnosed missing cases was substantial even with the stringent strategy adopted in Korea, similar to that of other countries.

Keyword

Antibody Test; COVID-19; Daegu; Hospital Visitors; Seroprevalence; Korea

Reference

1. Korea Centers for Disease Control and Prevention. Updated 2020. Accessed June 8, 2020. http://ncov.mohw.go.kr/en/.

2. Korean Society of Infectious Diseases. Korean Society of Pediatric Infectious Diseases. Korean Society of Epidemiology. Korean Society for Antimicrobial Therapy. Korean Society for Healthcare-associated Infection Control and Prevention. Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020; 35(10):e112. PMID: 32174069.

3. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, et al. Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward. Sci Immunol. 2020; 5(47):eabc6347. PMID: 32430309.

4. Shakiba M, Hashemi Nazari SS, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.04.26.20079244.

5. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020. JCM.00941-20.

6. Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Repeated seroprevalence of anti-SARS-CoV-2 IgG antibodies in a population-based sample from Geneva, Switzerland. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.05.02.20088898.

7. Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.04.26.20079822.

8. Erikstrup C, Hother CE, Pedersen OB, Mølbak K, Skov RL, Holm DK, et al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2020; ciaa849. PMID: 32584966.

9. Fontanet A, Tondeur L, Madec Y, Grant R, Besombes C, Jolly N, et al. Cluster of COVID-19 in northern France: a retrospective closed cohort study. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.04.18.20071134.

10. Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. J Med Virol. 2020; DOI: 10.1002/jmv.25904.

11. Slot E, Hogema BM, Reusken CB, Reimerink JH, Molier M, Karregat JH, et al. Herd immunity is not a realistic exit strategy during a COVID-19 outbreak. Updated 2020. Accessed June 5, 2020. DOI: 10.21203/rs.3.rs-25862/v1.

12. Streeck H, Schulte B, Kuemmerer B, Richter E, Hoeller T, Fuhrmann C, et al. Infection fatality rate of SARS-CoV-2 infection in a German community with a super-spreading event. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.05.04.20090076.

13. Silveira M, Barros A, Horta B, Pellanda L, Victora G, Dellagostin O, et al. Repeated population-based surveys of antibodies against SARS-CoV-2 in Southern Brazil. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.05.01.20087205.

14. Thompson C, Grayson N, Paton R, Lourenço J, Penman B, Lee LN, et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.04.13.20060467.

15. Bendavid E, Mulaney B, Sood N, Shah S, Ling E, Bromley-Dulfano R, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.04.14.20062463.

16. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 323(14):1406–1407.

17. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis. 2020; 26(7):1470–1477. PMID: 32255761.

18. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis. 2020; 20(5):e102–7. PMID: 32145768.

19. Mallapaty S. Will antibody tests for the coronavirus really change everything? Nature. 2020; 580(7805):571–572. PMID: 32313159.

20. Vogel G. First antibody surveys draw fire for quality, bias. Science. 2020; 368(6489):350–351. PMID: 32327574.

21. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis. Diagnostics (Basel). 2020; 10(5):319.

22. Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020; 52(5):737–741. PMID: 32433946.

23. Kwok KO, Lai F, Wei WI, Wong SY, Tang JW. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020; 80(6):e32–3. PMID: 32209383.

24. Gomes MG, Corder RM, King JG, Langwig KE, Souto-Maior C, Carneiro J, et al. Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity threshold. Updated 2020. Accessed June 5, 2020. DOI: 10.1101/2020.04.27.20081893.

25. Leslie M. T cells found in coronavirus patients ‘bode well’ for long-term immunity. Science. 2020; 368(6493):809–810. PMID: 32439770.

26. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020; 181(7):1489–1501.e15. PMID: 32473127.